KRAS and non-small cell lung carcinoma: While KRAS<sup>G12C</sup> inhibitors such as sotorasib and adagrasib are approved therapies, most patients with KRAS<sup>G12C</sup> mutant NSCLC experience disease progression within 5 to 6 months.